Mixed Q4, but targeted improvements hold the key
02/02/23 -"Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and Cardiovascular were partly offset by weaker dynamics ..."
Pages
69
Language
English
Published on
02/02/23
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...